Eton Pharmaceuticals to Report Fourth Quarter 2021 Financial Results on Wednesday, March 16, 2022
Eton Pharmaceuticals, Inc (Nasdaq: ETON) announced its fourth quarter 2021 financial results will be reported on March 16, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Eton Pharmaceuticals, Inc (Nasdaq: ETON) announced its fourth quarter 2021 financial results will be reported on March 16, 2022. Management will host a conference call and live audio webcast for investors at 7:00 p.m. ET due to ongoing litigation regarding their cysteine product. Investors can submit questions via email prior to or during the call. Eton currently holds six FDA-approved products and has four others submitted for approval, emphasizing their focus on rare diseases.
Positive
- Eton holds six FDA-approved products and has four additional product submissions.
Negative
- Cysteine product litigation ongoing may create uncertainty.
Details
News Market Reaction – ETON
The recorded move for ETON in the trading session of this news was +2.15%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DEER PARK, Ill., March 08, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report fourth quarter 2021 financial results on Wednesday, March 16, 2022. Due to the company’s cysteine product Paragraph IV litigation trial taking place during business hours on March 16, management will host a conference call and live audio webcast to discuss these results at 7:00 p.m. ET (6:00 p.m. CT).
In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can email questions to: investorrelations@etonpharma.com.
The live webcast can be accessed on the investors section of Eton’s website at https://ir.etonpharma.com/. The conference call can be accessed by dialing 1-866-795-8473 (domestic) or 1-470-495-9161 (international) and refer to conference ID 1318317. An archived webcast will be available on Eton’s website approximately two hours after the completion of the event and for 30 days thereafter.
About Eton Pharmaceuticals
Eton Pharmaceuticals, Inc. is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The company currently owns or receives royalties from six FDA-approved products, including ALKINDI SPRINKLE®, Carglumic Acid, Biorphen®, Alaway® Preservative Free, Rezipres®, and Eprontia™, and has four additional products that have been submitted to the FDA.
Investor Contact:
David Krempa
dkrempa@etonpharma.com
612-387-3740
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.